FDA panel backs Glaxo asthma drug for adults, not adolescents – Reuters


Channel News Asia

FDA panel backs Glaxo asthma drug for adults, not adolescents
Reuters
The panel voted 16 to 4 that the product, Breo Ellipta, should be approved for once daily treatment of asthma in adults 18 years and older. It voted 19 to 1 that the data did not support approval for use in children aged 12 to 17. The FDA is not
Critical inspection of GlaxoSmithKline plc (ADR) (NYSE:GSK) by FDA WallStreet.org
FDA panel backs Glaxo inhaler for adults, not adolescentsTown Hall
GSK and Theravance Announce Outcome of US FDA Advisory Committee on MarketWatch
Healio
all 12 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.